CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat drug-resistant bacteria. The portfolio includes early development pipelines of antibiotics, vaccines, and diagnostics to prevent, diagnose, and treat bacterial infections.

CARB-X

CrUX Dataset

Gravity Forms

CrUX Top 5m

Business Management

Richard Alm

Sales and Support

Ed T. Buurman, PhD, MBA

Director of Strategic Initiatives

Genevieve Holmes

Director Project Management Office

Kathleen Chardavoyne

Associate Director, Financial Systems & Reporting

Tina Mercado-Bradford

Accelerator Manager

Colin Mcgoodwin

Research Compliance Manager

Heather Tobin

Risk, Safety, Compliance

James Southard Esq.

Senior Alliance Manager

Nadia Cohen

Adjunct Principal Investigator

Ashley Stevens

Chief Scientific Officer

Kevin Outterson

Executive Director

Diane MacDonald

Chief Operating Officer

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need

Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.

Talis Biomedical is developing a point-of-care, sample-to-answer platform.

Specific Diagnostics is a medical device company that provides a patented technology leverages a low-cost small molecule sensor.

Zikani Therapeutics is a new anti-infective company founded to advance groundbreaking technology.

Evotec is a pharmaceutical and life science company that provides drug discovery and gene therapy solutions.

Mutabilis is discovery of new therapeutic targets for the development of anti-infectives.

Forge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.

Greater Boston Area Investors

Investors Active in Boston, Massachusetts

Investors Active in Utrecht

Accelerators with Investments in Texas

Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.

CARB-X Fund

Boston

Massachusetts

United States

North America

CARB-X funds Scout to develop a low-cost point-of-care diagnostic for STI testing

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

CARB-X gives funding to support Basilea’s recently acquired antibiotics program

Switzerland

Europe

Indonesia

Asia

Germany

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 3:43 AM	12948516
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 3:43 AM	28fd4be8
crunchbase trigger	general	Oct 29, 2024 5:10 PM	2fa52ac1
crunchbase profile	general	Oct 30, 2024 12:38 PM	2df28d05
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	a2368c8c
peers	general	Oct 16, 2024 3:43 AM	980c8453
news basic	general	Oct 16, 2024 3:43 AM	43fcbf3e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CARB

ORG:CARB-X

CARB-X